Expert Pitch
Rensselaer Polytechnic Institute (RPI)

Rensselaer Team Seeks Alternative Approach to Controlling Viruses

20-Mar-2020 8:55 AM EDT, by Rensselaer Polytechnic Institute (RPI)

As researchers worldwide scramble to formulate a vaccine to combat COVID-19, a team at Rensselaer Polytechnic Institute is pursuing a potentially powerful solution to pandemic control: a viral trap that is easily adapted to different classes of viruses, enabling a “plug-and-play” approach to virus detection and antiviral activity. 

Jonathan Dordick, an endowed professor of chemical and biological engineering at Rensselaer, and Robert Linhardt, an endowed professor of chemistry and chemical biology, said the team is exploring how their work — in the areas of viral detection, therapy, and inhibition — could be used against COVID-19 and other viruses in the future. Their team views such innovative approaches as a vital hedge against the growing threat of global pandemics. 

The viral trap works by mimicking the latch points on a human cell that a virus must bind to before infecting a person by disgorging its genetic instructions into the cell. In research on the Dengue virus with Xing Wang, now a professor of chemistry at the University of Illinois, recently published in Nature Chemistry, the team folded a snippet of DNA into a five-pointed star, and attached decoy latch points that align perfectly with the virus’ own molecular grappling hooks. The result was the world’s most sensitive test for Dengue, and a novel means of capturing and ultimately killing the virus. 

In previous research, the team demonstrated the same approach for Influenza A, and it can likely be expanded to other viruses like COVID-19. 

In another approach, Dordick demonstrated how enzymes incorporated into paint, can form a catalytic coating capable of killing the Influenza A Virus. The research, published in Applied Microbiology and Biotechnology, suggests enzyme systems could further be incorporated into swabs, wipes, or coatings, to target and kill various viruses, including COVID-19.




Filters close

Showing results

110 of 2539
Released: 13-Jul-2020 4:05 PM EDT
OADN & AACN Secure No-Cost Access to COVID-19 Screening Solution Until Vaccines Become Widely Available
Organization for Associate Degree Nursing (OADN)

OADN & AACN Secure No-Cost Access to COVID-19 Screening Solution Until Vaccines Become Widely Available

Newswise: Study suggests lymphoma drug acalabrutinib might offer a potential therapeutic approach for severe COVID-19 infection
Released: 13-Jul-2020 3:45 PM EDT
Study suggests lymphoma drug acalabrutinib might offer a potential therapeutic approach for severe COVID-19 infection
Hackensack Meridian Health

The mechanisms of action of acalabrutinib led to the hypothesis it might be effective in reducing the massive inflammatory response seen severe forms of COVID19. Indeed, it did provide clinical benefit in a small group of patients by reducing their inflammatory parameters and improving their oxygenation.

Newswise: National Virtual Biotechnology Laboratory Unites DOE Labs Against COVID-19
Released: 13-Jul-2020 3:40 PM EDT
National Virtual Biotechnology Laboratory Unites DOE Labs Against COVID-19
Department of Energy, Office of Science

To focus its efforts against the COVID-19 pandemic, DOE is bringing the national laboratories together into the National Virtual Biotechnology Laboratory.

Newswise: Key Insights from Swedish Casino that Remained Open During COVID-19
Released: 13-Jul-2020 3:40 PM EDT
Key Insights from Swedish Casino that Remained Open During COVID-19
University of Nevada, Las Vegas (UNLV)

As casinos in Las Vegas enter the second month of reopening since the COVID-19 pandemic took hold, UNLV gaming researchers say they can draw upon insights from industry collaborators in Sweden, a country that took a more open approach to the crisis compared to other governments.

Released: 13-Jul-2020 3:05 PM EDT
Asymptomatic Transmission and Reinfection of COVID: Live Event for July 16, 2PM EDT
Newswise

Emerging data shows more risk of asymptomatic transmission and reinfection with COVID than previously thought. Experts will discuss these findings and what are the implications for managing the pandemic. Media are invited to attend and ask questions.

Released: 13-Jul-2020 2:40 PM EDT
Engineered llama antibodies neutralize COVID-19 virus
Rosalind Franklin Institute

Antibodies derived from llamas have been shown to neutralise the SARS-CoV-2 virus in lab tests, UK researchers announced today.

Released: 13-Jul-2020 1:25 PM EDT
1 in 3 young adults may face severe COVID-19
University of California, San Francisco (UCSF)

As the number of young adults infected with the coronavirus surges throughout the nation, a new study by researchers at UCSF Benioff Children's Hospitals indicates that youth may not shield people from serious disease.

Released: 13-Jul-2020 12:25 PM EDT
Scientists discover key element of strong antibody response to COVID-19
Scripps Research Institute

A team led by scientists at Scripps Research has discovered a common molecular feature found in many of the human antibodies that neutralize SARS-CoV-2, the coronavirus that causes COVID-19.

Released: 13-Jul-2020 11:15 AM EDT
UTHealth joins study of blood pressure medication’s effect on improving COVID-19 outcomes
University of Texas Health Science Center at Houston

An interventional therapy aimed at improving survival chances and reducing the need for critical care treatment due to COVID-19 is being investigated by physicians at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is underway at Memorial Hermann and Harris Health System’s Lyndon B. Johnson Hospital.


Showing results

110 of 2539

close
1.67655